Cargando…
Design, Synthesis and Structure-Activity Relationship Optimization of Lycorine Derivatives for HCV Inhibition
Lycorine is reported to be a multifunctional compound. We previously showed that lycorine is an HCV inhibitor with strong activity. Further research on the antivirus mechanism indicated that lycorine does not affect the enzymes that are indispensable to HCV replication but suppresses the expression...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4595722/ https://www.ncbi.nlm.nih.gov/pubmed/26443922 http://dx.doi.org/10.1038/srep14972 |
_version_ | 1782393655116431360 |
---|---|
author | Chen, Duozhi Cai, Jieyun Cheng, Junjun Jing, Chenxu Yin, Junlin Jiang, Jiandong Peng, Zonggen Hao, Xiaojiang |
author_facet | Chen, Duozhi Cai, Jieyun Cheng, Junjun Jing, Chenxu Yin, Junlin Jiang, Jiandong Peng, Zonggen Hao, Xiaojiang |
author_sort | Chen, Duozhi |
collection | PubMed |
description | Lycorine is reported to be a multifunctional compound. We previously showed that lycorine is an HCV inhibitor with strong activity. Further research on the antivirus mechanism indicated that lycorine does not affect the enzymes that are indispensable to HCV replication but suppresses the expression of Hsc70 in the host cell to limit HCV replication. However, due to the cytotoxicity and apoptosis induction of lycorine, lycorine is unsafe to be a anti-HCV agent for clinical application. As a result of increasing interest, its structure was optimized for the first time and a novel series of lycorine derivatives was synthesized, all of which lost their cytotoxicity to different degrees. Structure-activity analysis of these compounds revealed that disubstitution on the free hydroxyl groups at C1 and C2 and/or degradation of the benzodioxole group would markedly reduce the cytotoxicity. Furthermore, an α, β-unsaturated ketone would improve the HCV inhibitory activity of lycorine. The C3-C4 double bond is crucial to the anti-HCV activity because hydrogenation of this double bond clearly weakened HCV inhibition. |
format | Online Article Text |
id | pubmed-4595722 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-45957222015-10-13 Design, Synthesis and Structure-Activity Relationship Optimization of Lycorine Derivatives for HCV Inhibition Chen, Duozhi Cai, Jieyun Cheng, Junjun Jing, Chenxu Yin, Junlin Jiang, Jiandong Peng, Zonggen Hao, Xiaojiang Sci Rep Article Lycorine is reported to be a multifunctional compound. We previously showed that lycorine is an HCV inhibitor with strong activity. Further research on the antivirus mechanism indicated that lycorine does not affect the enzymes that are indispensable to HCV replication but suppresses the expression of Hsc70 in the host cell to limit HCV replication. However, due to the cytotoxicity and apoptosis induction of lycorine, lycorine is unsafe to be a anti-HCV agent for clinical application. As a result of increasing interest, its structure was optimized for the first time and a novel series of lycorine derivatives was synthesized, all of which lost their cytotoxicity to different degrees. Structure-activity analysis of these compounds revealed that disubstitution on the free hydroxyl groups at C1 and C2 and/or degradation of the benzodioxole group would markedly reduce the cytotoxicity. Furthermore, an α, β-unsaturated ketone would improve the HCV inhibitory activity of lycorine. The C3-C4 double bond is crucial to the anti-HCV activity because hydrogenation of this double bond clearly weakened HCV inhibition. Nature Publishing Group 2015-10-07 /pmc/articles/PMC4595722/ /pubmed/26443922 http://dx.doi.org/10.1038/srep14972 Text en Copyright © 2015, Macmillan Publishers Limited http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Chen, Duozhi Cai, Jieyun Cheng, Junjun Jing, Chenxu Yin, Junlin Jiang, Jiandong Peng, Zonggen Hao, Xiaojiang Design, Synthesis and Structure-Activity Relationship Optimization of Lycorine Derivatives for HCV Inhibition |
title | Design, Synthesis and Structure-Activity Relationship Optimization of Lycorine Derivatives for HCV Inhibition |
title_full | Design, Synthesis and Structure-Activity Relationship Optimization of Lycorine Derivatives for HCV Inhibition |
title_fullStr | Design, Synthesis and Structure-Activity Relationship Optimization of Lycorine Derivatives for HCV Inhibition |
title_full_unstemmed | Design, Synthesis and Structure-Activity Relationship Optimization of Lycorine Derivatives for HCV Inhibition |
title_short | Design, Synthesis and Structure-Activity Relationship Optimization of Lycorine Derivatives for HCV Inhibition |
title_sort | design, synthesis and structure-activity relationship optimization of lycorine derivatives for hcv inhibition |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4595722/ https://www.ncbi.nlm.nih.gov/pubmed/26443922 http://dx.doi.org/10.1038/srep14972 |
work_keys_str_mv | AT chenduozhi designsynthesisandstructureactivityrelationshipoptimizationoflycorinederivativesforhcvinhibition AT caijieyun designsynthesisandstructureactivityrelationshipoptimizationoflycorinederivativesforhcvinhibition AT chengjunjun designsynthesisandstructureactivityrelationshipoptimizationoflycorinederivativesforhcvinhibition AT jingchenxu designsynthesisandstructureactivityrelationshipoptimizationoflycorinederivativesforhcvinhibition AT yinjunlin designsynthesisandstructureactivityrelationshipoptimizationoflycorinederivativesforhcvinhibition AT jiangjiandong designsynthesisandstructureactivityrelationshipoptimizationoflycorinederivativesforhcvinhibition AT pengzonggen designsynthesisandstructureactivityrelationshipoptimizationoflycorinederivativesforhcvinhibition AT haoxiaojiang designsynthesisandstructureactivityrelationshipoptimizationoflycorinederivativesforhcvinhibition |